A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer

Inclusion Criteria: * Over 18 years old. * Advanced cancer potentially sensitive to single agent docetaxel; ie.. locally advanced or metastatic breast cancer, locally advanced non-small cell lung cancer, hormone refractory metastatic prostate cancer, other tumor type with no standard treatment. * ECOG performance status of 0-2 and Karnofsky Score of 100-70. Exclusion Criteria: * Patients who have more effective therapy available than single agent docetaxel for the malignancy. * Pregnancy or lactation. * Intolerance to any antineoplastic agents belonging to the taxoid family. * Hypersensitivity to drugs formulated with polysorbate 80. * Active infection. * Prior anticancer therapy within 30 days prior to the first day of study treatment. * Participation in another experimental drug study within 30 days prior to the first day of study treatment.